By covalently binding to a cysteine residue within the BTK active site (IC50 = 0.5 nmol/L), ibrutinib irreversibly inhibits BTK activity, thereby suppressing malignant B-cell proliferation and migration to tumor-supportive lymphoid microenvironments [6,7]. The gene discussed is BTK; the disease is neoplasm.